Introduction
============

Liver cancer is currently the third most common cancer type and the second leading cause of deaths in men (521,000, 6.4% of the total, per annum; [@B18]; [@B49]; [@B60]). Despite the use of aggressive treatments, the 5-years survival rate for patients with liver cancer only varies around 10% and will remain a global health concern, especially in Asian countries ([@B48]; [@B18]; [@B176]). Hepatocellular carcinoma (HCC) has accounted for a majority (90%) of liver cancer cases. Risk factors leading to HCC comprise a medical history of chronic liver diseases, including liver cirrhosis, hepatitis, alcoholic and non-alcoholic fatty liver diseases (AFLD and NAFLD, respectively). NAFLD is characterized by abnormal accumulation of TAG in hepatocytes under metabolic and viral stimulation and it is reported to be one of the most prevalent causes of chronic liver diseases in Western countries, constituting an estimated prevalence of 20--40% ([@B165]; [@B27]). NAFLD may progress into NASH, cirrhosis and ultimately HCC ([@B163]).

Emerging evidence has ascribed the development of liver cancer to obesity and type 2 diabetes ([@B184]). The World Health Organization (WHO) categorizes a body mass index (BMI) ≥ 25 kg/m^2^ as overweight and a BMI ≥ 30 kg/m^2^ as obese. From 1980 to 2008, the worldwide prevalence of obesity has doubled, according to the statistics of WHO ([@B51]). Obesity does not only induce cancer-causing chronic inflammation, but also cause alterations in the endocrine system ([@B4]; [@B177]), which might altogether contribute to the increased risks for the development of NAFLD and HCC ([@B175]; [@B28]). Due to the difficult differentiation in a large scale, separate global estimates of prevalence for types 1 and 2 diabetes are not available ([@B117]). The skyrocketing increase in the number of diabetic patients estimated by WHO (fourfolds) from 1980 to 2014 has coincided with the current increase of liver cancer incidence ([@B117]). Indeed, a recent study has as well estimated that patients with a history of diabetes and/or obesity will exhibit a 2.47-fold higher liver cancer risk ([@B184]). The present epidemic of fat-associated metabolic syndromes is positively correlated to the increasing trend of HCC all over the world.

Sexual dimorphism is the biological inequality between males and females in disease initiation and progression. Deregulated signaling of sex hormones, i.e., androgen in males and estrogens in females, is believed to be one of the drivers of sexual dimorphism in HCC. The male-to-female ratio averages between 2:1 and 7:1 in virus and NAFLD-related HCCs ([@B127]; [@B63]; [@B44]; [@B163]). Recent population-based studies have consistently demonstrated much higher risk of HCC in obese men. In a prospective study including more than 900,000 adults, it was found that men with a BMI of 35 kg/m^2^ exhibited a dramatic 4.52-fold increase in relative risk of death from liver cancer, while a modest 1.68-fold increase was observed in women ([@B23]). A cohort study of 5.24 million adults in UK has further confirmed the significant modulation of HCC incidence by gender ([@B12]). More recently, a multi-ethnic cohort study has shown that BMI was strongly associated with HCC in Japanese, white, and Latino men ([@B12]). The multi-regional epidemiological studies have all revealed the high male-to-female ratio in both HCC incidents and risks, raising a question in how two genders differ in the pathogenesis of HCC.

While NAFLD-associated HCC is closely associated with deregulation in fat metabolism, gender dimorphisms may occur in our adipose homeostasis. Differences in body fat composition rather than BMI were suggested to be true determinants of HCC prognosis. Indeed, visceral adiposity can independently predict mortality in patients with HCC ([@B154]). Coincidentally, visceral fat accounts for a strikingly larger proportion of body fat in men than in women, indicating the potential importance of the studies into HCC-associated fat metabolism and the corresponding gender disparities ([@B58]; [@B154]).

Current studies in the gender disparities in HCC primarily focus on the deregulated signaling pathways and metabolism in hepatocytes. While abnormal fat metabolism plays a crucial role in the onset of HCC, the dramatic differences in the body fat distribution and the adipocyte depot-specific roles in different genders are seldom taken into account. We are presenting the current understanding of the gender disparities in the body fat composition and glycerol metabolism, and discuss the mechanisms by which these metabolic alterations potentially contribute to the contrasting number of incidents of HCC in males and females.

Adipocyte Metabolism and HCC
============================

Metabolic syndromes are closely associated with two types of white adipose tissues, visceral adipose tissue (VAT) and subcutaneous adipose tissue (SCAT). Gender disparities occur in the distribution and composition of body fat, which may help explain the cause for the strikingly higher HCC incidence in men. VAT differs from SCAT in terms of anatomy, cellular functions, molecular compositions, endocrine functions, and their response of insulin and other hormones. Anatomically, VAT and SCAT are categorized by their corresponding location of depots. Visceral fat is defined as the fat depots around the abdominal organs including the liver and the small intestine; subcutaneous fat, which is located at the femerogluteal regions, back and anterior abdominal wall, represents the physiological buffer for excess energy intake and accounts for around 80% of our total body fat ([@B178]). Visceral fat accumulates as the age increases in both genders ([@B178]). As mentioned, men possess nearly 30% more visceral fat than women, suggesting the promising field to study in resolving the relationship among adipocyte physiology, genders and HCC ([@B58]; [@B154]). Regarding their particular locations, visceral fat and subcutaneous fat employ different drainage routes of blood. Venous blood from VATs is circulated directly to the liver via the portal vein while subcutaneous fat venous blood is drained through systemic veins ([@B81]). Adipocytes are responsible for the storage of excess energy intake and the absorption of free fatty acids (FFAs) and triglycerides. Adipocytes get dysfunctional when they get hypertrophic ([@B74]). Adipocytes in VAT are generally bigger in size, hyperlipolytic, insulin-resistant and are molecularly different from those in the subcutaneous regions ([@B74]). The accumulation of visceral fat in the omental region promotes insulin resistance and its associated liver injury. The deregulated release of FFAs and glycerol from visceral adipocytes can also contribute to the onset of HCC. Considering the fact that visceral fat accumulates more in males and it causes a tumor-promoting condition in the liver, it is logical to postulate the intriguing relationship between fat metabolism and the gender dimorphisms in HCC.

The adipose tissue comprises multiple cell lineages including adipocytes, preadipocytes, vascular and neural cells and more importantly the immune cells ([@B74]; [@B62]). Early studies reported the increase in infiltration of inflammatory macrophages in VAT, which thus causes insulin resistance in mice and human ([@B183]; [@B20]; [@B114]). C-C motif chemokine receptor 2-knockout (Ccr2-KO) mice attributed insulin resistance in diet-induced obesity to the shift of from pro-inflammatory M1 macrophages into alternatively activated M2 macrophages and the reduction of anti-inflammatory cytokine interleukin-10 (IL-10) ([@B100]). The increased infiltration of inflammatory macrophages in visceral fat causes insulin resistance via the nuclear factor-κB (NF-κB) pathway ([@B92]). In general, visceral fat accumulation is accompanied with the increase in M1 macrophage population, nurturing an elevated local inflammation and a pro-carcinogenic environment within the adipose tissue. The accumulation of activated M2 macrophages in the abdominal adipose tissue remove the protective effect of IL-10 against tumor formation. The increased infiltration could also elevate the liver burden and gradually promotes HCC.

Both levels of visceral fat and HCC risks positively correlate with age and a masculine gender. In view of the harmful effects of visceral adiposity, the contrasting levels of visceral fat accumulation in males and females may help explain the gender disparities in immune responses ([@B82]) and HCC development ([@B163]).

Visceral Adipose Tissue and HCC
-------------------------------

Obesity is a heterogeneous disorder, with which obese individuals exhibit a wide range of body fat distribution and the associated metabolic profiles. Obesity is associated with excess body fat. Adipose tissue has long been considered as an inert storage of energy while more recent studies have pointed out its role in the immune and endocrine regulation ([@B21]). White adipose tissue can be subdivided into VAT and SCAT according to its distribution. VAT mainly deposits around the abdominal viscera in mesentery and omentum and is responsible for the "central obesity" phenomenon in which individuals have a greater risk of type 2 diabetes, cardiovascular diseases and obesity-related cancer ([@B111]; [@B130]; [@B74]; [@B188]). VAT and SCAT present very distinct physiological functions. VAT acts as a metabolically active endocrine organ secreting a number of adipokines for regulatory purposes ([@B74]). Visceral adiposity has been complicated with negative effects including insulin resistance and the elevated production of pro-inflammatory molecules leptin (LEP), resistin, tumor necrosis factor-α (TNF-α), IL-6, hypoxia-inducible factor 1 (HIF-1) and adipocyte fatty-acid binding protein (A-FABP) ([@B183]; [@B187]; [@B62]; [@B160]; [@B132]). Excess absorption of fat from the diet enlarges adipocytes and stimulates the release of FFAs ([@B74]) (**Figure [2](#F2){ref-type="fig"}**). Visceral fat is considered as a major source of FFAs in the portal vein, which can cause liver fat accumulation and the development of NAFLD ([@B128]). Adiposity has also been reported to associate with cancer-causing phenotypes including secretion of immune cell-attracting molecules (e.g., monocyte chemoattractant protein 1, MCP-1), angiogenesis, cellular senescence through microbial metabolites (e.g., deoxycholic acid, DCA), lipolysis and decreased production of adiponecitin ([@B197]; [@B19]; [@B43]; [@B50]; [@B196]) (**Figure [2](#F2){ref-type="fig"}**). FFAs-induced inflammation and insulin resistance leads to pathogenic endoplasmic reticulum stress and eventually fosters a tumor-promoting, low-grade chronic inflammatory microenvironment in the liver ([@B120]; [@B202]). A particular form of FFAs, linoleic acid, which is usually accumulated in NAFLD, has recently been ascribed to the disruption of mitochondrial function, oxidative damage and the selective loss of intrahepatic CD4^+^ T cells ([@B101]). Adiposity is closely associated with the immune cell population in liver. Alongside the chronic inflammation caused by the increase in FFA release, the loss of CD4^+^ T cells potentially results in the failure of recruiting innate immune cells to kill pre-malignant senescent hepatocytes and suggesting the role of an inflammatory microenvironment in HCC initiation. An increased population of B lymphocytes was found recruited in adipose tissue in obese subjects (**Figure [2](#F2){ref-type="fig"}**). B cells in obese mice favored the secretion of pro-inflammatory cytokines IL-6 and suppressed anti-inflammatory cytokines IL-10 ([@B186]). High-fat diets raised B cell population and caused insulin resistance in mice ([@B186]). VAT accumulation has also been proposed as an independent risk factor for HCC since visceral fat accumulation was positively correlated to the recurrence of HCC and the severity of fatty liver in NAFLD patients, but, interestingly, not SCAT ([@B120]). Cohort studies using computerized tomography (CT) to measure VAT have shown that visceral fat accumulation enhances the severity of hepatic inflammation and fibrosis in NASH, HCC risks as well as the recurrence of HCC after curative treatment ([@B174]; [@B120]; [@B177]; [@B152]). Furthermore, visceral fat accounted up to 10--20% of the total fat in men and 5--8% in women, whereas subcutaneous fat accounts for a significantly larger portion of total body fat in women as shown in different studies ([@B12]; [@B154]) (**Figure [1](#F1){ref-type="fig"}**). Emerging evidence in visceral fat accumulation points toward tumor formation and the differential body fat composition in males and females potentially results in gender disparities in HCC risks. The higher level of metabolically active VAT in males nurtures a pro-carcinogenic environment while the higher SCAT level in females may, on the other hand, offers a buffering and protective effect against HCC formation. Regarding the tumor-promoting properties of visceral fat and the coinciding gender dimorphisms in both liver cancer and visceral adiposity, the following session will focus on the underlying mechanisms (**Figure [2](#F2){ref-type="fig"}**).

![**Gender dimorphism occurs in the altered metabolic pathways that can lead to the progression of HCC.** Visceral adiposity can be observed more commonly in men and nurtures a pro-carcinogenic microenvironment that promotes HCC initiation.](fgene-07-00168-g001){#F1}

![**Visceral adiposity increases the release of pro-inflammatory adipokines and reduces the protective counterpart, causing immune cell infiltration, liver injury, and the subsequent pathological syndromes.** The increase in the release of FFAs and glycerol to the liver from visceral fat also promotes lipid peroxidation and thus increases HCC risks. MDSCs: myeloid-derived suppressor cells.](fgene-07-00168-g002){#F2}

In short, the higher level of VAT in males contributes to the likelihood of HCC initiation either by releasing pro-inflammatory adipokines, metabolites or immune cell infiltration.

Adipokines and HCC
------------------

Adipokines are peptides, proteins, and cytokines synthesized by the adipose tissue. Over 75 adipokines have been identified in adipose tissue, while only some of them are associated with carcinogenesis, especially the development of liver cancer ([@B168]; [@B190]; [@B202]; [@B21]). Classical examples of adipokines synthesized by dysfunctional obese adipose tissue are usually involved in localized chronic inflammation. Enlarged adipocytes in VAT liberates FFAs to stimulate adipose tissue macrophages to produce TNF-α, which in turns activate adipocytes to undergo lipolysis and secret multiple cancer-causing adipokines ([@B74]; [@B114]). MCP-1 is secreted by adipocytes to recruit macrophages and myeloid-derived suppressor cells (MDSCs) to local tissue and further worsen chronic inflammation ([@B197]; [@B121]) (**Figure [2](#F2){ref-type="fig"}**). Moreover, hypertrophied adipocytes are exposed to a hypoxic condition in which there is an elevated production of HIF-1, leading to the infiltration of macrophages and the secretion of adipokines ([@B167]) (**Figure [2](#F2){ref-type="fig"}**). The release of a pro-inflammatory cytokine IL-6 from hepatic stellate cells is associated with an increased level of FFAs in VAT ([@B185]; [@B196]). IL-6 is also associated with insulin resistance, fibrosis and tumorigenesis involving the activation of STAT3, Akt, Erk, JNK pathways ([@B185]; [@B126]).

Leptin is an important adipose-derived hormone involved in energy homeostasis, immune responses, angiogenesis, and insulin signaling ([@B53]). Leptin overexpression was found responsible for TNF-α and IL-6-related chronic inflammation, insulin resistance, liver fibrosis, and HCC development ([@B75]; [@B179]; [@B53]; [@B31]; [@B170]). Leptin has been reported to cause proliferation of HCC cells by altering the activity of cyclin D1 and the apoptotic gene, Bax ([@B31]). Leptin is also one of the reported biomarkers for early recurrence of HCC after treatment ([@B182]). Women require twice as high circulating leptin levels to maintain normal body weight and are more resistant to leptin activity than men do ([@B95]). The resistance to leptin in women potentially reduces the corresponding harmful effects. A reduction in leptin sensitivity may reduce cytokine-induced inflammation and insulin resistance. It is suggested that women are subject to a lower HCC risk due to a lower sensitivity to leptin.

Adiponectin is considered to play a protective role in cancer progression involving anti-inflammation, sensitization of insulin signaling and anti-angiogenesis. Adiponectin induces the production of IL-10, working together to inhibit inflammatory factors like IL-6 by inhibiting the NF- κB pathway cascade ([@B74]; [@B97]). Other anti-cancer mechanisms of adiponectin include promoting apoptosis in HCC cells and inhibit cell migration by inhibiting Akt/STAT3 signal transduction ([@B156]; [@B97]). Contradictory results showed the cancer-promoting role of adiponectin in HCC patients. A significantly higher level of serum adiponectin is reported in HCC patients and was also found guilty for tumor growth ([@B32]; [@B150]). Since the metabolic profiles in HCC patients have been severely altered, the implicit role of adiponectin regarding HCC development requires further investigations. Despite all these, it is generally believed that men with a higher level of visceral fat accumulation are more subject to a procarcinogenic microenvironment. Hormonal influences on adipocyte homeostasis could be one of the reasons for the differential visceral fat accumulation and the differences in adipokine production.

Gender Dimorphism In Adipocyte Metabolism
=========================================

Sex Hormones and Adipocyte Metabolism
-------------------------------------

Visceral fat deposition is significantly higher in males than in females whereas subcutaneous fat accumulates more in females ([@B74]). Having a similar total fat and BMI, males showed a higher visceral fat and liver fat content than females in multiple datasets ([@B12]; [@B154]). Obvious gender dimorphism was also observed in both diet-related liver diseases and HCC initiation ([@B28]). Visceral fat actively secrets oncogenic adipokines, leading to chronic inflammation and contributes to liver cancer. The disparities of liver cancer and visceral fat deposition potentially originate from high androgen receptor (AR) density ([@B54]). The increase in body visceral fat and the decrease in body subcutaneous fat as the age increases, coinciding with the increase with HCC incidence ([@B14]). Estrogen promotes the accumulation of subcutaneous fat and is protective against inflammation ([@B74]). After menopause, the rise of body VAT in women is related to the deficiency of estrogen ([@B14]; [@B54]). Signaling pathways involving sex steroids contribute to the differential secretion of cancer-causing adipokines in men and women, thus leading to a higher risk of HCC in men. Potential sexual dimorphism in HCC is also caused by the differential recruitment of Foxa-1/2 transcription factors and the corresponding androgen and estrogen receptors, showing the involvement of steroid hormones in liver cancer development ([@B94]). AR and ER can both act as transcription factors altering chromatin accessibility and gene transcription in HCC ([@B94]). Although limited studies using chromatin-immunoprecipitation-sequencing (ChIP-seq) have been done on adipocytes, it is postulated that the differential binding profiles of AR and ER in visceral fat and subcutaneous fat can help unveil the underlying mechanisms of androgen and estrogen in visceral adiposity and the subsequent side effects. The potential links may help understand the differences of adipokine profiles in men and women and thus explain how men get more prone to HCC initiation.

### Estrogen

Estrogen and estrogen receptor (ER) signaling have been found to have a protective role in HCC initiation and progression via the IL-6/STAT inflammatory pathways ([@B116]; [@B194]). One of the anticancer adipokines adiponectin is expressed at a higher level in women than in men ([@B91]). Estrogen replacement therapy helps decrease adiponectin circulation in postmenopausal women ([@B86]). It is reported that adiponectin is inversely associated with the incidence of multiple types of diet-related cancer ([@B72]). Adiponectin is associated with anti-inflammation, increasing insulin sensitivity and anti-angiogenesis, which coincides with the protectively role of estrogen signaling ([@B171]; [@B74]). A reduction of body estrogen after menopause is frequently followed by an increase in body visceral fat (increase in size of adipocytes), hyperinsulinemia and increase in IL-6 production ([@B54]). Estrogen offers a protective effect against metabolic deregulation and HCC. It is suggested that a reduction in the endogenous estrogen level causes a drop in adiponectin in postmenstrual women. The physiological mechanisms of estrogen on the release of adiponectin are a potential explanation for the gender dimorphism of HCC.

### Androgen

Regional androgen concentration in VAT suggests a depot-specific effect on adipocyte functions and metabolism ([@B9]). Androgen excess in female mice using 5α-dihydrotestosterone (DHT) treatment induced an increase in visceral fat deposition, via an altered hypothalamic axis ([@B119]). The complicated role of androgen signaling in body fat distribution and adipocyte functioning has long annoyed scientists for decades. Early studies revealed results on a reduced circulating androgen levels with visceral fat deposition ([@B59]; [@B169]; [@B84]). Androgen was shown to have a suppressive effect in adiponectin level consistently in cell lines, animal models, and human epidemiological studies ([@B118]; [@B90]; [@B76]; [@B124]). Such phenomenon explains how androgen undermines the anti-inflammatory effects of adiponectin and develops chronic inflammation in the liver. Regarding the regulation of androgen on genes involved in adipogenic genes, recent studies have discovered the role of microRNA miR-375 in adipocyte differentiation and distribution. Androgen treatment in preadipocytes could downregulate miR-375 expression and increase the level of adiponectin receptor 2 (ADIPOR2), which might help understand the mechanisms of how testosterone deficiency could lead to insulin resistance and visceral fat accumulation ([@B84]). Generally, visceral fat has a high density of AR, which allows testosterone to amplify its own effect by raising AR expression, inhibiting lipoprotein lipase and the uptake of FFAs ([@B178]; [@B54]). As men age, the bioavailability of testosterone declines and leads to the deposition of visceral fat. Yet, the case is opposite in women who exhibit an increase in androgen level released from the ovary when they are complicated with hyperinsulinemia and it is known as the polycystic ovary syndrome ([@B178]; [@B54]). *In vivo* and *in vitro* studies of leptin production varied greatly. Adipocytes from different locations reacted differently to androgen *in vivo* and *in vitro* ([@B104]). The difficulty of local application of androgen has long limited the physiological studies of how androgen affects a particular region of adipocytes and the following pathologies. Contrary to its involvement in HCC, androgen appears to inhibit visceral fat accumulation and the complicated association among androgen, visceral fat accumulation and liver cancer needs further investigation.

In short, the androgen to estrogen ratio determines the leptin and adiponectin levels and visceral adiposity. A higher androgen to estrogen ratio is associated with a respective higher leptin and lower adiponectin ratio in both genders. The high androgen to estrogen ratio is linked to metabolic syndromes and it is also predicted such phenomenon is one of the culprits for HCC initiation.

Gender-specific Single Nucleotide Polymorphisms in Adipose Tissue
-----------------------------------------------------------------

The large discrepancies in fat distribution and homeostasis in males and females imply potential genetic predispositions. Single nucleotide polymorphisms (SNPs) are enriched for expression of loci of quantitative traits and may alter gene expression ([@B45]). This mechanism has been argued to be a major driver in disease susceptibility by genetically altering the susceptibility of DNA methylation and thus affecting gene expression ([@B109]). It has been demonstrated for obesity, insulin resistance, inflammation, oxidative stress, and hypoxia, which are all driver components of HCC initiation ([@B109]). Such mechanism is also reported to be cell type-specific ([@B47]). Sex-specific SNPs are found potentially responsible for fat distribution and inflammation ([@B162]; [@B180]). [@B109] have summarized a panel of candidate genes which are epigenetically regulated through DNA methylation and are involved in lipid homeostasis, including *CEBPA, PPARA, LEP, MC4R, NPY, POMC, FTO, ADIPOQ, GLUT4, INS, HIF1A, IFNG, TNF, FASN, NR3C1, and UCP1* ([@B109]). Among all the epigenetic targets, sexual dimorphisms in the SNPs can be identified, including the Adiponectin, C1Q And Collagen Domain Containing gene (*ADIPOQ)* and the leptin gene *(LEP)*, which, respectively, encode for crucial players in visceral adiposity and liver cancer initiation, adiponectin and leptin (**Figure [3](#F3){ref-type="fig"}**).

![**Protective single nucleotide polymorphisms (SNPs) in ADIPOQ and LEP genes that lead to differential serum adiponectin and leptin levels occur frequently in females.** A respective higher adiponectin and a lower leptin level can be found in female subjects. SNPs in ADIPOQ and LEP genes potentially reduce HCC risks and development in women through inflammatory and oncogenic pathways.](fgene-07-00168-g003){#F3}

### ADIPOQ

*ADIPOQ* has a length of 1.579 kb and contains three exons, in which the transcription start site is located at exon 2 ([@B105]). Several SNPs inside the *ADIPOQ* gene have been associated with adiponectin serum levels, body adiposity and other metabolic alterations, rendering it a potential player in obesity and metabolic syndromes ([@B105]; [@B42]; [@B16]). Association studies of *ADIPOQ* polymorphisms, adiponectin levels and obesity phenotypes using samples of African American population from the Jackson Heart Study (JHS) cohort ([@B140]). Data collected from 2968 participants (1131men and 1837 women) revealed gender-specific association between SNPs rs6444174, rs1403697, and rs7641507 with serum adiponectin levels in women but not men ([@B140]). SNPs in *ADIPOQ* have also been reported to be associated with type 2 diabetes ([@B131]). SNPs at the adiponectin gene appear differently in men and women affecting circulating adiponectin, which may cause different adipocyte homeostasis and thus affecting the liver functions in a sex-specific manner.

### Leptin (LEP)

DNA polymorphism in the leptin gene is associated with tumorigenesis of multiple cancer types, such as lung cancer, lymphoma, thyroid cancer, and colon cancer ([@B159]; [@B98]; [@B173]; [@B107]). *LEP* is primarily expressed in differentiated adipocytes of white adipose tissue, and the hormone leptin it encodes for, plays a role in the regulation of food intake and the expression of energy-regulating peptides. *LEP* has been proposed as a culprit for obesity-induced cancer because it displays epigenetic variation and is involved in energy homeostasis, immune responses, angiogenesis and insulin signaling ([@B53]). Deregulated production of leptin or its receptor is highly associated with HCC development ([@B31]). Some Leptin G-2548A (rs7799039) polymorphism showed association with serum leptin level and obesity in young females only ([@B10]; [@B155]) (**Figure [3](#F3){ref-type="fig"}**). Since leptin is closely related to insulin signaling and inflammation, it is considered as a strong risk factor in obesity-related cancer. The gender dimorphism in the leptin gene may alter leptin secretion in adipocytes and eventually alter the cancer risk in different genders ([@B166]). On the other hand, when the preadipocytes mature, the gene is activated by DNA demethylation ([@B112]). Differences in the methylation status of the *LEP* promoter influence *LEP* expression *in vitro*, which approves the functional role of DNA methylation on leptin secretion in adipocytes ([@B135]). The establishment of epigenetic profiles is susceptible to maternal diets during early development ([@B36]). Female mice undertaking high-fat diets affected the offspring genes involved in fatty liver disease, lipid droplet size regulation and body fat expansion ([@B36]). The harmful effects of maternal diets on offspring have been reported to be organ-specific, gender-specific and remain at different life stages. The adult male offspring exhibited traits related to liver disease development overweight, insulin resistance, high leptin levels and hepatic steatosis but not the female counterpart, proving the possibility of gender-specific expression of leptin ([@B36]; [@B61]; [@B1]) (**Figure [4](#F4){ref-type="fig"}**).

![**Hypermethylation of *LEP* promoter in female offspring offers a protective effect against maternal high-fat diets by lowering leptin production in mice.** Maternal high-fat diets affect offspring's epigenetic regulation on the *LEP* gene. Obesogenic environments during the pre-conceptional period and the early phase of development led to a lower methylation state of the *LEP* promoter in male rodent offspring than their female counterparts. The higher leptin production in male offspring was also associated with overweight, insulin resistance and hepatic steatosis, which could help explain the gender dimorphism in leptin production and the development of liver diseases and HCC.](fgene-07-00168-g004){#F4}

Single nucleotide polymorphisms in the genes controlling expression of key adipokines leptin and adiponectin exert differential effects on males and females. Metabolic syndromes including type 2 diabetes and excess fat deposition could be caused by the differential expressions of *ADIPOQ* and *LEP* genes in males and females as a result of the respective SNPs.

GWAS studies rely heavily on the associations of gender-specific SNPs with metabolic traits such as insulin, leptin, adiponectin levels to support the fact that certain genetic predispositions leading to visceral fat accumulation and the release of leptin increases the risks of metabolic complications. The following challenge now is to understand the biological functions of those genes and how they are regulated differentially in males and females. In the aspect of genetics, mRNA expression profiles of such genes can be correlated with BMI, body fat distribution and our gender. Other possible mechanisms include epigenetic regulation via DNA methylation or histone modifications may be responsible for the association of the aforementioned traits with gender.

Epigenetic Regulation in Adipose Tissue
---------------------------------------

Epigenetic regulation of genes are considered to be important for disease pathogenesis since it is believed to translate environmental factors into phenotypic traits through alteration in the transcriptome ([@B52]; [@B151]).

### DNA Methylation

One of the many epigenetic mechanisms, methylation of CpG dinucleotides is proved to play crucial roles in the decision of cell fates, tumorigenesis and multiple cellular functions ([@B46]; [@B8]). DNA methylation usually occurs at CpG-rich regions and is often associated with gene repression ([@B13]). Epigenetics can provide insights for the understanding of chronic disease onset in adults, which interact with external stimuli like dietary intake and nutritional processes. Epigenetic regulations are believed to translate physiological impacts into altered gene expressions. Many genomic studies have reported the gene expression patterns in VAT, yet the differentially expressed genes may be functionally associated with visceral fat dysfunction and metabolic syndromes, including adipose tissue macrophage-specific genes and insulin resistance-related genes ([@B17]; [@B15]; [@B65]; [@B83]). Epigenetic mechanisms may contribute to the variability of the gene expression and the different components of metabolic syndromes. Transcriptional CpG-island promoter hypermethylation or global DNA methylation may affect the expression of genes controlling adipokine secretion, fat distribution, macrophage infiltration and insulin sensitivity. A recent genome-wide analysis of CpG methylation states of blood and adipose tissue from 479 individuals has revealed the association between DNA methylation and BMI ([@B41]). Data showed that the methylation level at three *HIF3A* sites was strongly correlated to BMI in adipose tissue, i.e., an increase in BMI was associated with an increase in methylation level at *HIF3A* sites. The HIF3A gene could not only respond to oxygen content locally, but it also played a role in cellular response to insulin and glucose and accelerated adipocyte differentiation in acquired obesity ([@B68]; [@B66]; [@B141]). Obesity has been reported to increase a global mean DNA methylation in adipocytes ([@B3]; [@B11]). Exercise can significantly influence the DNA methylation patterns in a genome-wide manner ([@B148]). Post-obese patients experienced a global DNA hypomethylation and differential methylation of adipogenesis genes ([@B37]). More DNA methylation in adipocytes can regulate different genes related to hypoxia and insulin sensitivity, providing a new scope for investigating the relationship between adipocyte homeostasis and liver cancer development.

Recent studies have also take advantage of cell lines and human mesenchymal stem cells in the study of DNA methylation in the transcriptional activation of leptin and adiponectin genes ([@B88]; [@B200]). On top of this, [@B2] have also demonstrated the differential expressions of genes encoding for epigenetic regulators in VAT and SCAT in mice. The adipocyte nuclei were immuno-captured from VAT and SCAT to resolve the difficulties of isolating mature adipocytes from adipose tissue. The differential expressions of chromatin remodeler proteins involved in DNA methylation and histone modification shed light on the studies of epigenetic regulation of gene expressions in adipose tissues, promoting the study in the gender disparities in adipocyte homeostasis through epigenetics. Possible mechanisms of such disparities may include the binding of transcription factors like AR and ER alongside other pioneer factors that affect the chromatin status ([@B77]).

### Histone Modifications

Histone modifications represent another important mechanism of epigenetic regulation ([@B8]). Histone acetyltransferases (HATs) and histone deacetylases (HDACs) have been shown to respond to regulatory signals involved in adipocyte differentiation and adipogenesis ([@B203]). HDAC9 negatively regulated adipogenic differentiation in HDAC9 overexpression and knockout experiments ([@B30]). During chronic high-fat feeding in mice, HDAC9 deletion was shown to offer a protective effect against metabolic diseases by increasing adiponectin expression ([@B29]). Histone deacetylase HDAC4 is repressed in exercise-induced DNA methylation, leading to a reduced repressive activity on glucose transporter GLUT4 and thus increasing adipocyte glucose uptake and lipogeneis ([@B148]). Recent studies have also shown the effect of H3K9 methylation at Cebpa and Pparg loci marked with H3K4me3 deposition limits CCATT/enhancer binding protein β binding and thus halting adipogenesis ([@B110]). Although very limited studies have been done on histone modification profiling in adipocytes, more and more evidence is pointing toward the roles of histone modifiers in adipocyte functions the pathological development of metabolic diseases. Epigenetic studies of adipocyte metabolism may shed light on the disease progression as well as the gender differences in metabolic diseases and HCC.

Gender Dimorphism in MiRNAs Actions in Adipocyte Tissue
-------------------------------------------------------

MicroRNAs (miRNAs) are small noncoding RNAs of 18--15 nucleotides that regulate the translation of messenger RNAs (mRNAs) through binding to their 3′-untranslated regions (UTRs) leading to translation inhibition and/or mRNA degradation ([@B189]). miRNAs are known to be involved in multiple biological functions, including cell proliferation, cell differentiation, metabolism, and immunity and in diseases such as cancer, cardiovascular diseases and type 2 diabetes ([@B113]). In adipocytes, the expression of miRNAs and the corresponding regulation are closely related to sex hormones androgen and estrogen, providing a promising scope to understand gender dimorphism in lipid metabolism.

### miR-125a/b

The miR-125 family comprises miR-125a and miR-125b with similar sequences. The miR-125 family has been reported to play a role in the initiation and progression of cancers by either acting as tumor suppressors or oncogenes ([@B35]; [@B80]). However, it is clear that miR-125a down-regulation is clear linked to the development of leukemia ([@B172]). MiR-125a is also found responsible in adipose tissue and immune development ([@B161]; [@B64]). MiR-125a targets and inhibits the expression of estrogen-related receptor alpha (ERRα), a nuclear receptor that plays an important role in a number of metabolic homeostasis processes, such as fatty acid metabolism ([@B73]; [@B79]). It was also found that miR-125a is overexpressed in diabetic rats as compared with non-diabetic ones ([@B70]). Intriguingly, the overexpression of miR-125a has been found to inhibit adipocyte differentiation and the underlying gender-specific mechanisms of how miR-125a works together with ERRα requires further investigation ([@B70]). Although the relationship of miR-125 and estrogen signaling in adipocytes has not been well established, estrogen is found to alter miR-125 family in other cell types. MiR-125b can be up-regulated by estrogen via ERα pathway, which thus protects against NAFLD in mouse hepatocytes by inhibiting fatty acid synthesis and preventing lipid accumulation in liver ([@B201]) (**Table [1](#T1){ref-type="table"}**).

###### 

Target genes, functions of sex hormone-associated miRNAs in adipocytes.

  miRNA      Expression in Obesity   Expression in T2D   Targets              Upstream                                                    Functions                                                                     Reference
  ---------- ----------------------- ------------------- -------------------- ----------------------------------------------------------- ----------------------------------------------------------------------------- --------------------------------------------------------------------
  miR-125a   Up                      Up                  Inhibit ERRα            ?                                                        Inhibit adipocyte differentiation; Inhibit ERRα; Reduce insulin sensitivity   [@B73]; [@B70]; [@B161]; [@B64]; [@B79]; [@B195]
  miR-125b   Down                    Down                   ?                 Up-regulated by ERα                                         Inhibit NAFLD; Inhibit lipid accumulation; Inhibit fatty acid synthesis       [@B192]; [@B122]; [@B201]
  miR-222    Up                      Up                  Inhibit ERα, GLUT4   Up-regulated by high glucose and estradiol                  Reduce insulin sensitivity                                                    [@B24]; [@B99]; [@B192]; [@B69]; [@B138]; [@B136]; [@B157]; [@B39]
  miR-301a   ?                       Up                  Inhibit AR              ?                                                        Promote metastasis; Increase TGF-β1 expression                                [@B40]; [@B133]; [@B125]; [@B191]
  miR-375    Down                    Down                Inhibit ADIPOR2      Induced by ERK-PPARg-aP2 signaling; Inhibited by androgen   Promote fat accumulation; Reduce insulin sensitivity                          [@B193]; [@B85]; [@B7]; [@B96]; [@B84]
                                                                                                                                                                                                                        

### miR-222

In a study of 3T3-L1 adipocytes, miR-222 was found upregulated when exposed to a high extracellular glucose concentration and in obese adipocytes ([@B192]; [@B69]). High estradiol concentrations in visceral adipocytes were reported to increase miR-222 expression and decrease ERα and GLUT4 expression ([@B157]). Previous findings have also demonstrated the role of estrogen, androgen, and other hormones in insulin sensitivity ([@B99]; [@B138]). High estrogen level can reduce insulin sensitivity by mediating ERα and ERβ ([@B5]). *In vivo* and *in vitro* studies indicated that a high concentration of estrogen could inhibit the expression of the insulin-sensitive transporter GLUT4 in adipose tissue, muscle, and liver ([@B24]). ERα was also found to be a direct target of miR-222 in breast cancer cells, with a specific binding site at the seed sequence of miR-222 ([@B136]). miR-222 could be an important regulator of ERα expression in insulin resistance. However, a clearer pathway needs to be elucidated by further overexpression of miR-222 to determine whether it directly acts on ERα and GLUT4 expression ([@B157]). Possible signaling pathways of the action of miR-222 includes β-catenin and TGF-β signaling ([@B136]) (**Table [1](#T1){ref-type="table"}**).

### miR-301a

Preadipocytes can proliferate and differentiate into an adipose deposit upon stimulation and leads to an increase in adipocyte numbers and leading to obesity ([@B149]). Although the relationship between preadipocyte infiltration and the initiation of HCC remains unclear, studies have shown that the recruitment of preadipocytes is responsible for enhancing prostate cancer invasion and breast cancer development ([@B134]; [@B191]). Preadipocytes were found to induce miR-301a to promote metastasis of prostate cancer by down-regulating AR ([@B191]). Down-regulation of AR could regulate translationally and increase TGF-β1 expression ([@B133]). Following the Smad signaling mediators, the down-regulation of AR consequentially activated target genes like matrix metallopeptidase 9 (MMP-9) and promote tumor metastasis ([@B40]; [@B181]). Although AR overexpression was present in progressive HCC, AR was also found to be essential in suppressing HCC metastasis in the later stage of tumor development ([@B198]; [@B102]). A high AR expression could reduce the phosphorylation and inhibit the activity of p38, NF-κB signaling and MMP-9 expression and the suppress HCC metastasis ([@B164]). The coinciding evidence of miR-301a expression and AR signaling in preadipocytes in different cancer types may help understand the gender disparity of late-stage HCC progression (**Table [1](#T1){ref-type="table"}**).

### miR-375

The direct binding of miR-375 was mentioned to locate at the 3′-UTR of murine and human ADIPOR2 ([@B85]; [@B84]). ADIPOR2, as a receptor for adiponectin, mediates to increased PPARα ligand activities and fatty-acid oxidation by regulating adiponectin and ADIPOR2 signaling in adipose tissue ([@B193]; [@B7]). The function of miR-375 was reported to be induced during adipogenesis and to promote adipocyte differentiation by suppressing ERK1/2 phosphorylation via the ERK-PPARg-aP2 signaling ([@B96]). Insulin resistance in adipocytes was associated with a low adiponectin receptor level ([@B7]). Increased expression levels of both ADIPOQ and ADIPOR2 could help prevent fat accumulation in liver and adipose tissue and led to increased insulin sensitivity ([@B103]). Studies also showed that the expressions of adipogenesis-promoting miR-375 and ADIPOR2 were decreased and increased, respectively, in androgen treatment ([@B84]). Inhibiting miR-375 could decrease adipocyte differentiation and increase ADIPOR2 protein expression ([@B84]). From the observations in separate studies, mR-375 may be responsible for the deterioration of insulin-resistance-related liver injury and may cause the difference in the visceral fat deposition and liver diseases in men and women when the body androgen level decreases with age ([@B6]) (**Table [1](#T1){ref-type="table"}**).

Emerging epigenetic studies in adipocytes reveal a range of regulatory mechanisms in adipogenesis, adipokine expression and other metabolic pathways. Although limited studies have been done in the epigenetic regulations in adipocytes to demonstrate gender dimorphisms, AR and ER have already been shown to alter the epigenetic profiles as a nuclear factor in HCC cells ([@B94]). Our body fat composition may as well be regulated epigenetically and lead to such gender disparities. The epigenetic mechanisms in adipocytes may provide insights in HCC development through metabolic deregulation. With the advancement of the nuclei capture technique in VAT and SCAT mentioned by [@B2] it will be promising to study the depot-specific and even gender-specific epigenetic profiles in adipocytes to unveil the underlying mechanisms in adipocyte homeostasis and its potential effects on HCC initiation.

Genders, Aquaglyceroporins and HCC
==================================

Glycerol-3-phosphate (G3P), which is also known as glycerol, is an important metabolite for the control of fat accumulation and is the responsible for triacylglycerols (TAGs) synthesis and glucose homeostasis. Circulating free glycerol results from lipolysis, diets or in the kidney reabsorption ([@B137]). Aquaglyceroporins (AQPs) are protein channels for the transport of glycerol, other small neutral solutes and water across adipocytes. AQPs are emerging as important players adipocyte homeostasis implicated with adiposity and the control of insulin resistance ([@B147]). Aquaglyceroporins are sub-classified into AQP3, 7, 9, and 10 which regulate transport of glycerol and insulin sensitivity in adipocytes ([@B55]). In line with the gender dimorphisms in glucose and fat metabolism, the different expressions of AQPs and glycerol transport in men and women are also observed in diet-induced diseases including insulin resistance and NAFLD ([@B142]; [@B147]).

Regarding the relationship between AQPs and HCC, emerging evidence has also been ascribing AQP deregulation in hepatocytes to the pathogenesis and, as well, the metastasis of NAFLD-associated HCC. AQP9 has been identified as an important glycerol transport pathway in hepatocytes to facilitate hepatic gluconeogenesis and TAG synthesis ([@B143]). AQP9 is the main aquaglyceroporin in the liver and is dramatically reduced in HCC and is localized at non-tumorigenic liver tissue ([@B123]; [@B139]; [@B33]). AQP9 knockdown in mice significantly alleviated NAFLD-related symptoms including intrahepatic lipid accumulation and high serum lipid level, possibly due to a decrease in glycerol import into hepatocytes thus reducing liver lipid accumulation ([@B22]). The results are controversial since the resulted AQP9 knockdown is not tissue-specific and a global effect of AQP9 is observed, including glycerol absorption. However, AQP9 down-regulation was found frequent in hepatic biopsies of obese patients with type 2 diabetes ([@B25]). A reduced AQP9 expression in HCC cells was shown to resist apoptosis and the respective overexpression could restore the cell responsiveness to apoptotic stimuli ([@B78]). Protein kinase A activator, dibutyrul cAMP, increased AQP9 expression in HCC cells and suppressed tumor growth *in vivo*, suggesting the important roles of hepatocyte AQP9 in HCC development ([@B129]). Experiments in the SMMC7721 cell line demonstrated the molecular mechanism of AQP overexpression on its tumor suppressive function. An increase in AQP9 expression repressed the PI3K/Akt pathway and thus increased forkhead box protein O1 expression and up-regulation of apoptotic caspase-3 ([@B93]; [@B199]). AQP9 downregulation also promoted HCC metastasis in mice ([@B199]). The observed down-regulation of AQP9 in hepatocytes in obesity, diabetes and HCC is believed to be a negative feedback response of high glycerol intake. AQP9 is important in controlling glycerol import in hepatocytes. A proper glycerol import is crucial in maintaining the gluconeogenic pathway in hepatocytes and a normal lipid metabolism in the surrounding adipose tissues. The up-regulation hepatic AQP9 expression was associated with the alleviation the NAFLD-associated symptoms ([@B146]). AQP9 in hepatocytes is considered to offer a protective effect on HCC initiation and metastasis. On top of the clear relationship between hepatocyte AQPs with HCC, the interactions between adipocytes and hepatocytes are crucial in studying NAFLD-related HCC development since the distinguishing difference in fat deposition in males and females also affect glycerol transport and the corresponding subsequences. The coinciding gender dimorphism in fat metabolism and HCC development show the prospect in the interrelation between adipocyte and hepatocyte homeostasis.

In adipocytes, AQP7 acts as the main pathway in facilitating release of glycerol, while the others, including AQP3, 10 and 11 contribute glycerol export to a lower extent ([@B143]; [@B89]; [@B106]). The expression of AQPs also appears to be location-specific. Visceral adipocytes exhibit a higher expression level of AQP3 and AQP7, which may result in the overall rise in the lipolytic rate and glycerol release from VAT ([@B115]; [@B145]). In contrast, subcutaneous fat with a lower AQP7 level may help promote glycerol accumulation and thus adipocyte hypertrophy ([@B145]). AQP regulation in adipocytes is crucial in maintain the fat and glucose homeostasis, i.e., a deregulation will lead to obesity and insulin resistance ([@B87]; [@B71]).

A higher plasma glycerol level can be observed in females, which can be explained by a higher body fat rate resulting in a faster glycerol turnover ([@B67]). Moreover, adipose tissues respond differently to adipokines, lipolytic hormones and probably sex hormones in men and women ([@B153]). Fasting studies and exercise studies have shown that women exhibit a significantly higher glycerol level than men, which may be ascribed to the differences in sensitivity to insulin, epinephrine, leptin and even neural activities ([@B34]; [@B38]; [@B56], [@B57]; [@B67]). Obesity is associated with a higher lipolytic rate, plasma FFAs and glycerol ([@B145]). A gender-specific effect of regular exercise has shown a higher expression of omental adipose AQP7 in females ([@B145]).

Besides differential AQP expression, gender dimorphisms also occur in the response to leptin. The adipokine leptin has a lipolytic activity and has been shown to repress AQP7 and AQP9 expression via the PI3K/Akt/mTOR signaling pathway in human adipocytes ([@B144]). The association between a higher expression of AQP7 in females and the leptin level requires further investigation ([@B158]; [@B36]). Leptin stimulates translocation of AQP7 to the cytoplasm to facilitate glycerol release from adipocytes ([@B146]). At the same time leptin can also downregulates AQP7 mRNA to prevent depletion of fat stores ([@B146]). Long-term leptin administration in male leptin-deficit mice could downregulate AQP3 and AQP7 could help alleviate lipid accumulation in adipose tissue and liver ([@B144], [@B146]). However, the miscellaneous functions of leptin contradict in the development of obesity and liver cancer ([@B146]). The rescuing effect of leptin in NAFLD in leptin-deficient obese mice could be due to the neuroactive effects of leptin, but not as adipokines promoting local inflammation around internal organs. AQP7 is downregulated in women with severe obesity and this trait is limited to obesity but not type 2 diabetes ([@B26]). The downregulation of AQP7 was also reported to increase susceptibility of obesity by promoting lipid accumulation in the adipose tissue ([@B108]). The complicated association between NAFLD and AQPs involve not only adipocyte glycerol transport, but also the glucose and glycerol transport in hepatocytes. Mechanistic delineation of leptin in adipocytes is required to elucidate its relationship with liver cancer initiation.

Concluding Remarks
==================

Deregulated energy homeostasis and metabolic disorders induced by obesity and type 2 diabetes are key but largely unresolved issues in HCC development. The alterations in genetic, epigenetic and miRNA control of lipid and glucose metabolism, oxidative stress and the production of pro-inflammatory and anti-inflammatory cytokines contribute to the multiple-step development of NAFLD, NASH, cirrhosis and eventually HCC. The increased incidence of HCC associated with metabolic syndrome is significantly associated with the male gender. Sexual dimorphism as exemplified by the androgen and estrogen signaling pathways shapes the fat distribution in the body, contributing to the differential exposure to pro-inflammatory cytokines and lipotoxic adipokines which influence hepatic malignant transformation. Further mechanistic delineation of adipocyte metabolism via sex hormones using systems approach will shed light on the multifaceted roles of aberrant fat accumulation in HCC initiation and progression.
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